Biologic Therapy

Patients with psoriasis initially treated with infliximab or adalimumab had an increased risk for serious infection; however, those treated with IL-12/23, IL-17 or IL-23 inhibitors had a lower infection risk, according to a study.

Patients with elderly-onset rheumatoid arthritis have similar disease activity and adverse-event risk responses to biologics as nonelderly patients, according to data published in The Journal of Rheumatology.

Biologic infusions administered at home are associated with a 25% increased risk for hospital admission the same or next day, and a 28% higher risk for permanent discontinuation, compared with facility-given infusions, according to data.

The American College of Rheumatology has released an updated position statement declaring biologic infusions should be administered in a monitored health care setting rather than in the patient’s home, as some insurers have mandated.

Switching to bimekizumab resulted in better outcomes among certain patients with psoriasis who did not respond as well to adalimumab, according to results presented at AAD VMX 2021.

New data presented at AAD VMX 2021 suggest that certain clinical and demographic factors may affect patient perceived remission of psoriasis.

The ability to identify the features of Sjögren’s syndrome, and to seek payer approval for specific manifestations of the disease, is of paramount importance for the rheumatologist, according to a presenter at the 2021 Interdisciplinary Autoimmune Summit.

Healio spoke with Debu Tripathy, MD, about the importance of breast cancer awareness.

In a new study, adherence to asthma biologic therapy was higher than adherence to inhaled corticosteroids among adults with asthma.

Treating psoriasis and psoriatic disease during the COVID-19 pandemic has proven to be challenging for many providers.